Touyun Biotech Group (1332) Fair Value & Analysis
Consumer Cyclical · HK · Market cap HK$359M
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 3 days ago
Share price −8.6% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0700 – HK$1.69 · fair‑value band HK$0.1200 – HK$0.2000 · the HK$0.1480 price screens below the HK$0.1600 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Touyun Biotech Group (1332) currently trades at HK$0.1480, while our model-based Fair Value estimate is HK$0.1600, implying the stock looks roughly 8.1% fairly valued today. The Quality Score stands at 36/100 (below-average quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Touyun Biotech Group generated revenue of HK$67.0M at a net margin of 40.0%. Revenue declined 58.6% year over year. Net debt stands at HK$409M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.1200 (bear case) to HK$0.2000 (bull case); at HK$0.1480, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Consumer Cyclical peers we cover trades at -23% fair-value upside, at 8%, 1332 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: DCF Models (HK$0.2500) versus Multiples (HK$0.0400). Highest evidence: Growth-Adj P/E (68).
Notify me when 1332 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Touyun Biotech Group Limited, an investment holding company, manufactures and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. The company operates through three segments: Packaging Products Business, Treasury Investment Business, and Chlamydomonas Reinhardtii Products Business.
Full company description
Touyun Biotech Group Limited, an investment holding company, manufactures and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. The company operates through three segments: Packaging Products Business, Treasury Investment Business, and Chlamydomonas Reinhardtii Products Business. The Packaging Products Business segment manufactures and sells watch and jewelry boxes, eyewear cases, bags and pouches, and display units. The Treasury Investment Business segment invests and trades in securities, as well as offers money lending. The Chlamydomonas Reinhardtii Products Business segment produces and sells chlamydomonas reinhardtii, micro-algae, and related products. It also provides securities trading, brokerage, asset management, and corporate management services. The company was formerly known as China Touyun Tech Group Limited and changed its name to Touyun Biotech Group Limited in May 2021. Touyun Biotech Group Limited was founded in 1989 and is headquartered in Wan Chai, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Touyun Biotech Group reported revenue of HK$67.0M in FY2025 versus HK$284M in FY2021, a compound −30.3%/yr. Reported net income was HK$26.8M in FY2025.
Watch 1332: get an alert when its fair value changes →
Peer Group
Packaging & Containers · 273 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaging & Containers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaging & Containers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Stora Enso Oyj STER | kr 106.80 | kr 125.82 | +18% |
| ShenZhen YUTO Packaging Technology Co 002831 | ¥27.73 | ¥20.16 | -27% |
| SCG Packaging Public Company SCGP | 31.00 THB | 16.12 THB | -48% |
| AblePrint Technology Co 7734 | 3,350 TWD | 675.50 TWD | -80% |
| PT Fajar Surya Wisesa Tbk, FASW | 5,312 IDR | 1,193 IDR | -78% |
| Taiwan Hon Chuan Enterprise Co 9939 | 134.00 TWD | 127.06 TWD | -5% |
| Time Technoplast Limited TIMETECHNO | ₹208.56 | ₹161.42 | -23% |
| EPL Limited 500135 | ₹247.30 | ₹111.65 | -55% |
| Dongwon Systems Corporation 014820 | 21,650 KRW | 31,473 KRW | +45% |
| PT Panca Budi Idaman Tbk, PBID | 525.00 IDR | 774.13 IDR | +47% |
Compare Touyun Biotech Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Touyun Biotech Group (1332) overvalued or undervalued?
What is the fair value of 1332?
What is the quality score of 1332?
What is the revenue of Touyun Biotech Group (1332)?
What is the net profit margin of 1332?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Touyun Biotech Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.